Top Page
Eco Animal Health
(LSE:EAH)
Eco Animal Health (EAH) vs. S&P 500 (SPY)
Eco Animal Health Business Overview & Revenue Model
Eco Animal Health Financial Statement Overview
| Breakdown | ||||
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 89.42M | 85.31M | 82.19M | 105.61M | 72.11M | Gross Profit |
| 37.68M | 36.75M | 33.70M | 51.54M | 32.41M | EBIT |
| 3.54M | 5.05M | 4.53M | 16.90M | 6.50M | EBITDA |
| 6.48M | 7.41M | 3.62M | 18.63M | 7.97M | Net Income Common Stockholders |
| 1.05M | 1.01M | -686.00K | 7.34M | 3.90M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 22.37M | 21.66M | 14.31M | 19.52M | 11.88M | Total Assets |
| 123.27M | 121.31M | 113.60M | 116.89M | 99.99M | Total Debt |
| 4.03M | 4.48M | 1.91M | 1.52M | 3.80M | Net Debt |
| -18.35M | -17.18M | -12.40M | -18.00M | -8.08M | Total Liabilities |
| 29.89M | 25.76M | 19.25M | 21.57M | 19.54M | Stockholders Equity |
| 83.69M | 83.27M | 82.06M | 81.90M | 74.68M |
| Cash Flow | Free Cash Flow | |||
| 4.94M | 10.03M | -3.25M | 11.04M | 1.63M | Operating Cash Flow |
| 9.42M | 16.01M | -358.00K | 12.11M | 4.51M | Investing Cash Flow |
| -3.42M | -5.98M | -2.88M | -1.06M | -2.88M | Financing Cash Flow |
| -3.69M | -2.40M | -3.31M | -684.00K | -8.67M |
Eco Animal Health Technical Analysis
Eco Animal Health Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | £178.88M | 29.05 | 19.61% | 3.72% | 10.32% | 1.25% | |
75 Outperform | £165.56M | 4.55 | 33.70% | 2.08% | -0.17% | 2591.96% | |
62 Neutral | £43.37M | 64.43 | 0.80% | ― | -4.37% | ― | |
62 Neutral | £1.37B | 147.63 | -0.73% | 1.59% | -0.22% | -111.98% | |
52 Neutral | $5.17B | 3.59 | -42.19% | 2.82% | 15.05% | -0.04% |
Eco Animal Health Corporate Events
Eco Animal Health Group PLC has announced a significant change in its shareholder structure, with Schroders PLC increasing its stake in the company to 19.038827% from a previous position of 18.272461%. This acquisition of shares by Schroders PLC, a major investment management company based in London, highlights increased confidence in Eco Animal Health’s market positioning and potential growth prospects, which could have implications for the company’s strategic direction and stakeholder interests.
Spark’s Take on GB:EAH Stock
According to Spark, TipRanks’ AI Analyst, GB:EAH is a Neutral.
Eco Animal Health’s overall stock score reflects a stable financial position bolstered by a strong balance sheet and positive corporate events. However, profitability challenges, declining cash flow, and high valuation metrics weigh down its attractiveness. Technical indicators suggest caution, although recent strategic moves may offer potential upside if operational efficiencies improve.
To see Spark’s full report on GB:EAH stock, click here.
ECO Animal Health Group PLC announced that its CEO, David Hallas, has purchased 29,962 ordinary shares of the company at a price of 66.75 pence per share, increasing his total holdings to 154,797 shares. This move reflects confidence in the company’s growth prospects and could positively influence investor sentiment, reinforcing ECO’s position in the competitive animal health market.
Spark’s Take on GB:EAH Stock
According to Spark, TipRanks’ AI Analyst, GB:EAH is a Neutral.
Eco Animal Health has a stable financial position with a strong balance sheet but faces challenges in profitability and cash flow. Positive corporate actions and strategic refocusing on core areas provide potential upside. However, the high P/E ratio and technical indicators warrant caution. The stock scores moderately, reflecting both its strengths and risks.
To see Spark’s full report on GB:EAH stock, click here.
ECO Animal Health Group PLC has announced that its adjusted EBITDA for the year ended 31 March 2025 is expected to be slightly above market expectations due to strong trading in the final quarter, robust overhead cost control, and gross margins exceeding 45%. Despite challenges such as currency headwinds and geopolitical uncertainties, the company managed to achieve this profitability. However, group revenue is anticipated to be approximately 7% below market expectations. The company is taking proactive measures to mitigate the impact of US trade tariffs and continues to invest in new product innovation, particularly in its R&D pipeline, which is expected to drive future growth.
Spark’s Take on GB:EAH Stock
According to Spark, TipRanks’ AI Analyst, GB:EAH is a Neutral.
Eco Animal Health scores moderately due to a stable financial position and positive corporate events. However, the high P/E ratio and weak technical indicators suggest caution. The company’s efforts to streamline operations and focus on core sectors like pigs and poultry are promising, but profitability and valuation concerns weigh down the stock’s attractiveness.
To see Spark’s full report on GB:EAH stock, click here.
ECO Animal Health Group PLC is hosting an R&D Day to provide insights into its R&D pipeline, which is expected to drive long-term value creation and innovation in preventative animal health. The event, led by the company’s CEO and CFO, will not present new trading information but will offer investors and analysts a deeper understanding of the company’s future strategies. The company plans to release a trading update in April 2025.
ECO Animal Health Group has submitted a Marketing Authorisation Application to the European Medicines Agency for its ECOVAXXIN® Mycoplasma synoviae vaccine, marking a significant milestone in its vaccine development portfolio. This submission, slightly ahead of schedule, aligns with ECO’s commercialisation strategy and is expected to take 18 months for approval. The vaccine targets Mycoplasma synoviae, a significant poultry disease that causes economic losses due to reduced egg production and increased mortality. The company is also pursuing US marketing approval for the vaccine, anticipating simultaneous approval with Europe, and is working on a sister vaccine for Mycoplasma gallisepticum.
Eco Animal Health Group PLC has announced a change in its voting rights, following an acquisition or disposal of shares by Killik & Co LLP. The transaction, which took place on February 20, 2025, resulted in Killik & Co LLP holding 3.0659% of the voting rights in the company, up from a previous position of 3.0157%. This change reflects a slight increase in their stake, indicating a potential strategic interest in the company’s operations and future direction.
ECO Animal Health Group has sold certain non-core product lines, specifically ECOmectin licenses for sheep and cattle in Southern Africa, to a distribution partner for £491,000. This strategic move allows the company to sharpen its focus on its core business of pigs and poultry, reinvesting the proceeds into its R&D pipeline for new vaccines and preventatives, and potentially a share buy-back, subject to shareholder approval, to satisfy future employee share incentives.
ECO Animal Health Group announced an upcoming R&D Day scheduled for 13 March 2025, where the company’s leadership will present insights into their R&D pipeline to investors and analysts. This event is part of ECO’s strategy to showcase innovations in preventative animal health, aimed at driving long-term value creation and reinforcing its industry position.